What are the methods for fading acne marks?

There are several evidence-based approaches to help fade post-inflammatory hyperpigmentation (PIH)—commonly referred to as “acne marks” or “dark spots”—which occur after acne lesions heal. Unlike true scars (which involve structural skin damage), PIH results from excess melanin deposition triggered by inflammation. Effective management requires patience, sun protection, and often a combination of topical agents and procedural interventions.

First and foremost, daily broad-spectrum sunscreen with SPF 30 or higher is non-negotiable. Ultraviolet radiation stimulates melanocytes and can worsen or prolong pigmentation; consistent photoprotection is the foundation of any treatment plan. Topical therapies include hydroquinone (2–4%, typically used for limited durations under supervision), azelaic acid (15–20%), niacinamide (4–5%), vitamin C (L-ascorbic acid, 10–20%), and retinoids (e.g., tretinoin 0.025–0.1%). These agents work via distinct mechanisms—such as inhibiting tyrosinase, reducing oxidative stress, normalizing keratinocyte turnover, or suppressing melanosome transfer—and are often used in sequence or combination for synergistic effects.

For more persistent cases, dermatologist-performed procedures may be indicated. Chemical peels (e.g., glycolic, salicylic, or mandelic acid) promote epidermal exfoliation and accelerate pigment clearance. Intense pulsed light (IPL) or Q-switched lasers target melanin selectively, though caution is warranted in darker skin types (Fitzpatrick IV–VI) due to risks of rebound hyperpigmentation or hypopigmentation. Microneedling is generally less effective for pure PIH but may be considered if mixed scarring is present.

It’s important to note that improvement typically takes 8–12 weeks or longer, depending on depth, duration, and skin type. Avoid picking at active acne, as this increases inflammation and PIH risk. If pigmentation fails to improve after 3–6 months of consistent, appropriate therapy—or if lesions are atypical, rapidly changing, or associated with systemic symptoms—prompt evaluation by a board-certified dermatologist is recommended to rule out other diagnoses such as melasma, lichen planus pigmentosus, or early lentiginous melanocytic lesions.